Frontline Therapy and MRD: Exciting New Data from France

Submitted by Dr. Brian GM Durie on Thu, 07/31/2014 - 00:00

A recent study illustrates just how useful minimal residual disease (MRD) testing by flow cytometry is to predict excellent outcomes with new highly active combination therapies.

US Myeloma Flow Workshop in New York

Submitted by Dr. Brian GM Durie on Thu, 07/24/2014 - 00:00

On July 18-19, 2014, the IMF co-hosted the US Myeloma Flow Workshop at the Zuckerman Research Center at the Memorial Sloan Kettering Cancer Center in New York City. There were 24 participating medical centers from across the country plus representatives from the National Cancer Institute (NCI) and US Food and Drug Administration (FDA) in attendance.

Black Swan Research Initiative: As We Move Ahead, What Will We Learn?

Submitted by Dr. Brian GM Durie on Thu, 08/22/2013 - 00:00

The Black Swan Research Initiative team has been busy since our spring launch. Team members are laying the groundwork for clinical trials and perfecting the extra-sensitive testing regimes that will allow us to measure minimal residual disease, identify pathways to cures, and improve treatments along the way. 

Black Swan Research Initiative Researchers Speak Out and Publish

Submitted by Dr. Brian GM Durie on Thu, 07/11/2013 - 00:00
As the Black Swan Research Initiative (BSRI-- the IMF's innovative approach to finding a cure for myeloma --moves forward since its official launch in March, more and more myeloma researchers are contributing to the framework that is necessary to reach the project's key objectives.

IMWG Research Takes Center Stage at Summit in Stockholm

Submitted by Dr. Brian GM Durie on Thu, 06/20/2013 - 00:00

At the 4th Annual International Myeloma Working Group Summit, which just wrapped up in Stockholm, important questions were again considered by over 70 IMWG myeloma researchers from 29 different countries.

Pages